BRIEF-Atossa receives positive interim review from safety committee in Endoxifen study

* Atossa Genetics receives positive interim review from independent safety committee in phase 1 Endoxifen dose escalation study
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.